Trial · NCT07887763
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 25
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with Treatment Emergent Adverse Events (TEAEs) | Up to approximately Day 29 | |
| Primary | Number of participants with Serious Adverse Events (SAEs) | Up to approximately Day 29 | |
| Primary | Number of participants with Vital Signs abnormalities | Up to approximately Day 29 | |
| Primary | Number of participants with Physical Examination abnormalities | Up to approximately Day 29 | |
| Primary | Number of Participants with 12-Lead Electrocardiogram (ECG) abnormalities | Up to approximately Day 9 | |
| Primary | Number of Participants with Holter ECG abnormalities | Up to Day 2 | Part A |
| Primary | Number of participants with Clinical Laboratory abnormalities | Up to approximately Day 29 | |
| Primary | Number of participants with suicidal ideation and behavior assessed by Columbia Suicide Severity Rating Scale (C-SSRS) | Up to Day 9 | |
| Primary | Time of maximum observed blood concentration (Tmax) | Up to Day 6 | Part B |
| Primary | Maximum observed blood concentration (Cmax) | Up to Day 6 | Part B |
| Primary | Apparent total body clearance (CL/F) | Up to Day 6 | Part B |
| Primary | Apparent volume of distribution during the terminal phase (Vz/F) | Up to Day 6 | Part B |
| Primary | Apparent Terminal Phase Half-life (T-HALF) | Up to Day 6 | Part B |
| Primary | Geometric mean ratios (GMRs) of Cmax | Up to Day 6 | Part B |
| Primary | GMRs of AUC(0-T) | Up to Day 6 | Part B |
| Primary | GMRs of AUC(INF) | Up to Day 6 | Part B |
| Primary | Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) | Up to Day 6 | Part B |
| Primary | Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) | Up to Day 6 | Part B |
| Secondary | Time of maximum observed blood concentration (Tmax) | Up to Day 7 | |
| Secondary | Maximum observed blood concentration (Cmax) | Up to Day 7 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07887763/registered